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Abdominal aortic aneurysm (AAA) is a common cause of morbidity and mortality and has a significant heritability. We carried out
a genome-wide association discovery study of 1866 patients with AAA and 5435 controls and replication of promising signals (lead
SNP with a p value < 1 3 105) in 2871 additional cases and 32,687 controls and performed further follow-up in 1491 AAA and
11,060 controls. In the discovery study, nine loci demonstrated association with AAA (p < 1 3 105). In the replication sample, the
lead SNP at one of these loci, rs1466535, located within intron 1 of low-density-lipoprotein receptor-related protein 1 (LRP1) demon-
strated significant association (p ¼ 0.0042). We confirmed the association of rs1466535 and AAA in our follow-up study (p ¼ 0.035).
In a combined analysis (6228 AAA and 49182 controls), rs1466535 had a consistent effect size and direction in all sample sets (combined
p¼ 4.523 1010, odds ratio 1.15 [1.10–1.21]). No associations were seen for either rs1466535 or the 12q13.3 locus in independent asso-
ciation studies of coronary artery disease, blood pressure, diabetes, or hyperlipidaemia, suggesting that this locus is specific to AAA.
Gene-expression studies demonstrated a trend toward increased LRP1 expression for the rs1466535 CC genotype in arterial tissues; there
was a significant (p ¼ 0.029) 1.19-fold (1.04–1.36) increase in LRP1 expression in CC homozygotes compared to TT homozygotes in
aortic adventitia. Functional studies demonstrated that rs1466535 might alter a SREBP-1 binding site and influence enhancer activity
at the locus. In conclusion, this study has identified a biologically plausible genetic variant associated specifically with AAA, and we
suggest that this variant has a possible functional role in LRP1 expression.Introduction
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as 0.7.3–5 This strong genetic determination in the etiology
of AAA has led to multiple candidate gene association
studies of AAA, the majority of which have yielded find-
ings that have not been replicated in independent cohorts,
but with meta-analysis suggesting common variants in
ACE (MIM 106180), MTHFR (MIM 607093), and MMP9
(MIM 120361) might all be contributory.6 Two replicated
loci for AAA have been identified on 9p21.37 (which is
also associated with coronary artery disease [MIM 611139]
and intracranial aneurysm [MIM 611892]) and in DAB2IP
(MIM 609205) on 9q33.2 (also associated with early-onset
myocardial infarction, venous thromboembolism, and
peripheral arterial disease).8 Other risk factors for AAA
include age, male gender, and tobacco smoking.9–11 By
contrast, diabetes has been shown to be a negative risk
factor for AAA,11 whereas hypertension and hypercholes-
terolaemia, which are strong risk factors for other arterial
diseases, are inconsistent risk factors for AAA.
The strong heritability of AAA and the low odds ratio for
currently identified risk alleles suggests that other impor-
tant risk loci for AAA remain to be identified. In an effort
to identify new risk alleles for AAA, we undertook a
GWAS in 1866 patients with AAA and 5435 controls and
replication of promising signals in 2871 additional cases
and 32,687 controls and performed a further follow-up
study of 1491 AAA and 11,060 controls.Material and Methods
Study Design and Subjects
We assembled cases of AAA together with available DNA recruited
in eight centers in the UK, Australia, and New Zealand and
also samples from the United Kingdom Small Aneurysm Trial
(Table S1, available online) none of which had been used in any
previous genome-wide association study (GWAS) of AAA cases
were recruited from inpatient populations, outpatient clinics, or
population screening programs in the participating centers. AAA
ascertainment (infrarenal aortic diameter of >30 mm) was by
either ultrasonography or by cross-sectional imaging except for
patients who presented with acute rupture and for whom it was
assumed that the AAA was >5.5 cm. Some of the centers also
collected controls screened as being free of AAA by ultrasonog-
raphy (Table S1). In addition to these assembled samples, control
data from theWellcome Trust Case Control Consortium (WTCCC)
2 study were obtained. The study flow is shown in Figure S1. All
samples contributing to this study were collected under the
approval of the ethics committee responsible for each center and
informed consent was obtained from all individuals.
A genome-wide discovery study was performed by comparing
data from 1866 cases with AAA and 5435 unscreened controls
from the WTCCC2 study consisting of samples from the 1958
British Birth Cohort and from the UK National Blood Service.
The lead SNP for each locus identified in the discovery study
with a p value less than 1 3 105 was tested for replication by
genotyping 1579 independent AAA cases and 2184 screened
controls. In silico replication data for these lead SNPs from the
discovery study was obtained from a previously published, inde-
pendent GWAS of 1292 individuals with AAA and 30,503
controls.8 A follow-up study of SNPs demonstrating association620 The American Journal of Human Genetics 89, 619–627, Novembwith AAA in the replication studies was performed in independent
samples (11,090 controls and 1491 AAA) from the Copenhagen
City Heart Study and the Viborg Country AAA screening program
and samples collected by two of the contributing centers during
the conduct of the discovery and replication studies.
Genotyping
DNA samples for the discovery and replication studies were pro-
cessed at the Wellcome Trust Sanger Institute. Genomic DNA
was quantified by PicoGreen assay and quality control assured
by both agarose gel electrophoresis and Sequenom iPLEX geno-
typing of 29 SNPs and four gender markers. Genotyping for the
discovery study was performed with Illumina 1.2M (controls) or
670K (AAA) BeadChips. Raw intensity data were normalized
with BeadStudio, and genotypes were called concurrently from
the combined case control data set with the Illuminus algo-
rithm.12 Replication study genotyping was performed with Seque-
nom’s iPLEX assay. Follow-up studies of rs1466535 in the samples
from Copenhagen, Leeds, Otago, and Viborg were performed with
the TaqMan allelic discrimination method (with a predesigned,
functionally tested assay). All genomic information was refer-
enced to genome build 37.1/dbSNP build 132.
Quality Control
Quality control (QC) in the discovery study was first performed by
exclusion of SNPs with call rates of less than 0.98 and those that
demonstrated significant deviation from Hardy-Weinberg equilib-
rium in the control group (p < 0.0001). Duplicate samples and
those that failed genotyping (sample call rate 0.98) were also
excluded from further analysis. Genotyping cluster plots for all
SNPs with p values less than 1 3 104 were visually inspected to
exclude from further analysis positive associations generated by
erroneous genotyping or calling. Checks for population stratifica-
tion were first performed by PLINK13 identical-by-state clustering
and extreme outliers were removed from the analysis. Further
checks for population stratification were performed by multidi-
mensional scaling and subsequent analyses were adjusted for the
dimensions of this analysis. In total, 29,826 SNPs and 191 individ-
uals (23 AAA and 168 controls) were excluded from the analysis as
a result of quality control measures.
Association Analysis
Statistical analyses were performed with PLINK.13 The association
between genotype and AAA was tested with a Cochran-Armitage
test for trend in the discovery, replication, and follow-up studies,
and Fishers method was used to combine p values in the replica-
tion studies. Two-tailed Cochran-Armitage tests were applied in
all cases. The threshold chosen for statistical significance was
adjusted with a Bonferroni correction in the replication analysis.
Although this study was not powered to detect gene-environment
interactions, we performed additional exploratory analyses to
determine the independence of the SNPs identified from other
risk factors for AAA. Adjusted analyses for SNPs of interest were
carried out with a genotypic logistic regression model with the
presence or absence of individual risk factors entered as covariates
into separate models to examine each risk factor.
Imputation
Focused regional imputation was used to infer genotypes for SNPs
previously associated with AAA where these SNPs (or any SNP in
perfect linkage disequilibrium [LD]) were not directly typed orer 11, 2011
had failed tomeet quality control thresholds (rs1333049). Imputa-
tion was conducted with MACH 1.014 run on the BCjSNPmax
database platform (version 3.5, BC Platforms). The reference
haplotypes were the 1000 Genomes Project (June 2010), CEU
population (Utah residents with ancestry from Northern and
Western European ancestry from the CEPH collection). Subse-
quent calls were filtered by quality score (>0.9) to identify high
quality SNP’s.Association Analysis of rs1466535 with
Cardiovascular Risk Factors and Coronary Disease
In order to determine whether rs1466535 was associated
with cardiovascular risk factors or coronary disease, associ-
ation results for rs1466525 were obtained from large-scale
GWAS meta-analyses examining blood lipid levels,15 dia-
betes,16 hypertension,17 and coronary artery disease.18
Expression Analyses
To investigate whether there was any effect of rs1466535
on LRP1 expression in relevant tissues, we examined data
from an existing genome-wide eQTL study of samples of
ascending aorta, mammary artery, and liver taken from
patients undergoing aortic valve surgery.19 Aortic biopsies
were divided into intimal and adventitial halves. Periaortic
fat was removed from the adventitial specimens where
present. RNA from the tissue biopsies was hybridized to
Affymetrix ST 1.0 Exon arrays and obtained scans were
RMA normalized and log2 transformed. eQTL analysis
was performed with genotypes from circulating blood
DNA (Illumina 610w-Quad BeadArrays). Estimates of
rs1466535 genotype effect on LRP1 expression was calcu-
lated with an additive linear model. No correction for
multiple hypothesis testing was performed. Expression
analyses were conducted with Bioconductor 2.7.20 Full
methods for this study have been described previously.19
Potential Functional SNPs at 12q13.3
To assess whether rs1466535 is linked to any potential
functional SNPs, we first identified all SNPs in LD with
rs1466535 (r2 threshold > 0.2) with SNAP21 and the
1000 Genomes Project pilot 1 data set. Potential functiona-
lilty of these variants (splice-site variation or peptide-shift)
was then assessed by querying dbSNP 132 with Biomart.
Electrophoretic Mobility Shift Assay
Electrophoretic mobility shift assays (EMSAs) were per-
formed to determine whether rs1466535 had any effect
on localized DNA-protein interaction. Nuclear extracts
were obtained from Huh7 cells with the NE-PER Nuclear
and Cytoplasmic Extraction Reagents Kit (Pierce, North-
umberland, UK), with the addition of Complete Protease
Inhibitor (Roche, West Sussex, UK) to buffers CER I and
NER I. EMSA probes were designed with ~15 bp on each
side of the candidate SNP. Probes were labeled with the
Biotin 30 End DNA Labeling Kit (Pierce, UK). Probes were
analyzed in isolation and bound to unlabelled probeThe Americancompetitors, a sterol regulatory element-binding protein 1
(SREBP-1)22 competitor and a random oligonucleotide
competitor. Samples were loaded onto a 6% polyacryl-
amide gel and electrophoresed for 150 min at 120 V at
4C. Transfer to positively charged nylon membrane was
achieved through Southern transfer and detection with
the Chemiluminescent Nucleic Acid Detection Module
(Pierce, UK). Each binding reaction consisted of 2 ml of
103 binding buffer (100 mm Tris, 500 mm KCl [pH 7.5]),
1 mg of p[dI-dC], 5 mg of nuclear extract, and 200 fmol
of biotin-labeled DNA made to a total of 20 ml with
H2O and incubated at 25
C for 30 min, followed by the
addition of 53 loading buffer. Primers for rs1466535
were designed based on genomic sequences surrounding
the SNP (Table S2).
Luciferase Assay
A LRP1 promoter construct (previously described22) was
kindly provided by Dr. Llorente-Corte´s. The LRP1 pro-
moter (þ421 to 1350) was inserted into the restriction
sites (NheI and HindIII) of the pGL3-basic vector poly-
linker site. A rs1466535 intron 2 construct (C genotype)
was developed by PCR performed on 30 ng genomic
DNA with 13 NH4 polmix (16 mM (NH4)2SO4, 67 mM
Tris [pH 8.3], 0.01% Tween 20, 0.2 mM dNTPs each),
3 mM MgCl2, 0.1U Taq Polymase Bioline and 2 pmol
forward and reverse primers (Tables S3 and S4). PCR condi-
tions were as followed: 1 cycle at 95C for 2 min; 30 cycles
at 95C for 30 s, at 62C for 30 s, and at 72C for 30 s;
followed by 1 cycle at72C for 5 min. This resulted in
a 240 bp fragment, in the forward and reverse orientation.
PCR products were ligated into the 30 end of the LRP1
promoter clone at the SalI and BamHI sites with T4 ligase
(NEB) according to manufacturer guidelines and then
transformed into DH5a. To create the alternate variant
(T genotype), we performed site directed mutagenesis by
using the Quick Change Lightning Site-Directed Mutagen-
esis Kit (Stratagene) according to themanufacturer. All new
clones were checked by direct sequencing.
Huh 7 immortal hepatocellular carcinoma cells were
chosen for the luciferase assay because these cells contain
large quantities of SREBP-1. Huh7 cells were cultured
in Dulbecco’s Modified Eagle’s Medium (DMEM) High
Glucose (4.5 g/l), supplemented with 10% fetal bovine
serum. Cultures were grown and maintained at 37C con-
taining 5% CO2. Cells were plated out into a 96-well plate
at a concentration of 23 104 per well the day before trans-
fection to be 70% confluent at the time of transfection.
Transfection was carried out with Lipofectamine 2000
(Invitrogen) according to the manufacturer’s instructions.
Cells were lysed 48 hr after transfection. Luciferase assays
were carried out with the Dual Luciferase Reporter Assay
System from Promega according to the manufacturer’s
instructions. Each construct was replicated 12 times in
five different experiments. Luciferase activity was normal-
ized by the Renilla values and is expressed in normalized
fold change activity to the LRP1 promoter construct,Journal of Human Genetics 89, 619–627, November 11, 2011 621
Figure 1. Whole-Genome Manhattan Plot of the Results of the Discovery Study
p values expressed as a negative logarithm are plotted on the vertical axis and chromosomal positions of each SNP are plotted on the
horizontal axis. SNPs with p values < 1 3 105 are shown in red, and represent the loci taken forward into the replication study.which does not include the intron 2 variant. Mean relative
expression differences were calculated with a t test.Results
Discovery Stage
Following stringent quality control, we tested 535,296
SNPs for association with AAA in 1866 cases (mean AAA
size, 4.8 cmandmedian age, 72 years) and 5435 unscreened
controls (median age in the UK Blood Transfusion Service
samples was 45 years and all individuals in the 1958 Birth
Cohort were 52 years old at the time of analysis). Iden-
tical-by-state clustering identified 23 genomic outliers in
the AAA group and 168 in the control group that were
excluded from further analyses. Further checks for popula-
tion stratification were performed by multidimensional
scaling (Figure S2) that revealed potential stratification
and the analysis was therefore adjusted for the first six
dimensions fromthis analysis. The genomic inflation factor
(l) was calculated as 1.096 following these exclusions
(Figure S3), and an adjustment for thiswas applied in subse-
quent analyses. Following these adjustments, nine loci
demonstrated association with AAA at a p value threshold
of 13 105 (Figure 1 and Table S5) and were taken forward
for replication.Replication Stage
The discovery genome-wide association analysis identified
nine loci that demonstrated an association with AAA with
a p value < 1 3 105, and one lead SNP from each of these
loci was taken forward for replication. Replication was per-
formed in 2871 cases and 32,687 controls, comprising
1579 cases (mean AAA size, 5.4 cm and median age,
72 years) and 2184 screened controls (median age, 68
years) who underwent wet-lab replication and 1292 cases
and 30,503 controls with in silico data8 (Table S5).
rs1466535 (risk-allele frequency [C] ¼ 0.68 and discovery
p value 9.99 3 107) at 12q13.3 demonstrated significant622 The American Journal of Human Genetics 89, 619–627, Novembassociation in the replication study (p ¼ 4.23 103) allow-
ing for multiple testing (Bonferroni corrected replication
study p value threshold 0.0056) (Table 1). The regional
discovery study association plot and LD plot for 12q13.3
are shown in Figure 2.
None of the other variants taken forward to replication
showed significant association (Table S5) In particular
SNP rs3019885 (risk-allele frequency [T] ¼ 0.51) at
8q24.11 reached genome-wide significance in the dis-
covery study (p value 1.24 3 1010), but there was no
consistent evidence for association in the replication
samples (Table S5). Notably for this variant, the observed
effect direction in the in silico data from Iceland was
reversed compared to the other replication data sets and
the discovery study. To ensure that this observation was
not due to erroneous calling, we checked the frequencies
of a SNP in LD with rs3019885 (rs2938864) in the Iceland
data set and found them to be consistent. Because of the
lack of replication, this locus was not carried forward for
any further analyses.
rs1466535 genotypes were determined in a further
follow-up sample comprising 1491 AAA and 11060
controls, and this again confirmed the association of
rs1466535 and AAA (p ¼ 0.035) (Table 1). When all the
samples genotyped for rs1466535 were analyzed together
(6228 AAA, 49,182 controls), the combined p value was
4.52 3 1010 (odds ratio [OR] 1.15 [1.10–1.21]) with a
consistent effect direction in all sample sets (Table 1).
Little change in effect size was seen for rs1466535 when
the combined discovery and wet-lab replication samples
(those samples that had AAA size data available, 2871
cases and 7619 controls) were stratified by AAA size. In
those with AAA < 4.5 cm, the OR for rs1466535[C] was
1.18 (1.07 to 1.30, p ¼ 7.6 3 104), and in those AAA R
4.5 cm, the rs1466535[C] OR was 1.21 (1.12 to 1.31, p ¼
2.7 3 106). Aortic size was not assessed as a quantitative
trait because the method of measuring aortic size was not
standardized between or within the centers contributing
to the study. Because the method used to assess aortic sizeer 11, 2011
Table 1. Association of rs1466535 in LRP1 on Chromosomal Region 12q13.3 with AAA
Controls AAA
OR (95% CI) p value PhetN AF n AF
Genome-wide analysis
Discovery 5435 0.63 1866 0.68 1.22 (1.13–1.32) 9.99 3 107
Replication
Iceland 27,712 0.58 452 0.61 1.12 (0.98–1.28) 0.10
Netherlands 2791 0.65 840 0.68 1.14 (1.02–1.28) 0.026
Laboratory 2184 0.65 1579 0.68 1.12 (1.02–1.23) 0.02
Combined replication studies 1.13 (1.06–1.19) 0.0042 0.97
Combined discovery and replication studies 1.16 (1.11–1.23) 2.86 3 109 0.49
Follow-up studies
Leeds 254 0.64 216 0.67 1.12 (0.95–1.33) 0.38
Viborg 196 0.64 503 0.66 1.07 (0.94–1.22) 0.60
Otago 430 0.61 579 0.66 1.23 (1.04–1.45) 0.028
Copenhagen 10,180 0.63 193 0.65 1.04 (0.96–1.12) 0.64
Combined follow-up studies 1.11 (1.01–1.23) 0.04 0.60
Overall combined analysis
(6228 AAA, 49,182 controls)
1.15 (1.10–1.21) 4.52 3 1010 0.67
Results for the genome-wide analysis, replication, and follow-up studies of the SNP rs1466535 in LRP1 associated with AAA. Allele frequencies (AF) shown are for
the risk (C) allele. Association testing was performed with the Cochran-Armitage trend test (two-tailed) analysis in the discovery study corrected for a genomic
inflation factor of 1.096 and the first six components of a multidimensional scaling analysis. Two-tailed Cochran-Armitage trend tests were used in the replication
and follow-up studies. The genome-wide discovery study was performed comparing a pooled AAA case set from contributing centers with the WTCCC2
unscreened controls. The laboratory replication study was performed with a pooled case and control set (not all centers contributed both cases and controls
to the analysis). The control samples used in the genome-wide analysis, and the studies from Iceland and Copenhagen were not screened for the presence of
AAA. The combined analysis was performed by generic inverse variance weighted meta-analysis with a fixed effects model (Phet is the p value for Cochrans Q
test for heterogeneity). The overall combined analysis of the discovery, replication and follow-up studies is shown in bold type.has a considerable effect on the measured size, this hetero-
geneity would result in a lack of power to detect any associ-
ation. This effect is limited by the dichotomization of the
data as adopted here. rs1466535[C] frequencies for each
center contributing to the discovery and replication studies
are shown in Table S6. Those for the studies contributing to
the in silico replication and follow-up studies are shown in
Table 1.
Two further SNPs previously reported to be associated
with AAA were also genotyped in the replication samples
(chr9p21 rs1333049 and DAB2IP rs10818583 [a proxy for
rs7025486]).7,8 rs1333049 demonstrated highly significant
association in both the discovery data set (p¼ 8.913 105,
based on imputed data) and the replication data set (p ¼
3.3 3 105), combined odds ratio of 1.15 (95% confidence
[CI]: 1.09 to 1.22, p ¼ 4.4 3 107). rs7025486 (DAB2IP)
showed a borderline association in the discovery stage
(p ¼ 0.027). In the replication stage, rs7025486 again
showed borderline association (p ¼ 0.048), resulting in
a combined p value of 9.9 3 103 (OR 1.09, 95% CI: 1.02
to 1.16). When samples contributing to the GWAS that
identified this association were removed from the replica-
tion analysis, the effect size for rs7025486 remained the
same but at a reduced level of significance (p ¼ 0.017, OR
1.098 [0.89–1.35]).The AmericanTo assess whether the association of the 12q13.3 locus
with AAA is driven by the presence of clinical factors
associated with AAA, we performed an analysis with
adjustment for self-reported history of hyperlipidaemia;
smoking; or diabetes, which has a negative association
with AAA, in subjects where this information was available
and found that the association was independent of each of
these factors (Table S7). By examining previous genome-
wide meta-analyses of lipid traits, diabetes, and blood
pressure, we also confirmed that there is no association
of this locus with these traits (Table S8). Because AAA
and coronary artery disease (CAD [MIM 608320]) often
coexist, we also carried out an analysis adjusted for the
presence of overt CAD in our subjects and showed that
the association with AAA was still significant (Table S7),
and by an examination of the locus in the CARDIoGRAM
study18 we showed that the locus does not show a signal
for CAD (Figure S4). These data indicate that the observed
association of the locus with AAA is independent of
conventional risk factors for AAA and not due to confound-
ing by the concomitant presence of CAD in the cases.
Functional Assessment of rs1466535
SNP rs1466535 is located in the second intron of the
low-density-lipoprotein receptor-related protein 1 (LRP1Journal of Human Genetics 89, 619–627, November 11, 2011 623
Figure 2. GWAS Discovery Study Associations
for the Region around rs1466535 Showing All
Genes in the Region
rs1466535 is indicated by the purple circle, the
other SNPs typed in the discovery study are
shown as filled circles with the color correspond-
ing to their linkage with rs1466535. The solid
blue line shows the regional recombination
rate (right axis). Below the regional association
plot is the LD plot for the same region with the
standard D’/LOD Haploview color scheme.
rs1466535 is highlighted by green lines.
Table 2. Effect of rs1466535 Genotype on LRP1 Expression
Tissue Number
CC versus TT
Fold-Change (95% CI)
Aortic adventitia 133 1.19 (1.04–1.36)
Aortic intima media 138 1.17 (0.96–1.42)
Mammary artery intima media 89 1.24 (0.99–1.56)
Liver 212 0.99 (0.91–1.07)
Tissue samples were obtained from 316 patients undergoing aortic valve
surgery; 572 unique tissue samples were analyzed. Extracted RNA was hybrid-
ized to Affymetrix ST 1.0 Exon arrays and obtained scans were RMA normalized
and log2 transformed. DNA was extracted from circulating blood cells and
hybridized to Illumina 610w-Quad BeadArrays. rs1466535 genotype was
directly measured. Estimates of genotype effect on expression of genes were
calculated with an additive linear model. The fold-change is calculated as the
difference between the mean expression levels in the CC homozygotes
compared to the TT homozygotes. Values greater than one correspond to
higher expression in CC homozygous individuals. The results for aortic adven-
titia are shown in Figure S5.[MIM 107770]) gene (Figure 2). There are no known non-
synonymous SNPs or splice-site variants in linkage disequi-
librium (r2 > 0.2) with rs1466535. We therefore examined
whether rs1466535 was associated with expression of any
of the genes at the locus. Expression QTL data sets were
available for liver and two arterial tissues (the internal
mammary artery and ascending aorta). There was a trend
toward increased LRP1 expression with the rs1466535
CC genotype in all arterial tissues with a significant (p ¼
0.029) 1.19-fold (1.04–1.36) increase in LRP1 expression
level in CC homozygotes compared to TT homozygotes
in aortic adventitia (Figure S5 and Table 2).
SREBP-1 is known to play a role in transcriptional
regulation of LRP1.22 We noted that there was sequence
homology between the SREBP-1-binding sequence and
the region containing rs1466535. To assess whether
rs1466535 affects SREBP-1 binding, we performed an elec-
trophoretic mobility-shift assay (EMSA) and found selec-
tive binding of nuclear extract from Huh7 cells to an oligo-
nucleotide representing the C allele that was competed out
by excess amount of a probe competitor for SREBP-1
(Figure 3). These results indicate that the rs1466535 Tallele
might disrupt a binding site for SREBP-1.
In order to determine the possible transcriptional effect
of the rs1466535 variant, a luciferase reporter system was
created whereby the LRP1 promoter was inserted upstream
of luciferase and the sequence containing the two different
genotypes of rs1466535 were placed downstream, in both624 The American Journal of Human Genetics 89, 619–627, November 11, 2011reverse and forward directions. Figure S6
shows the relative changes in luciferase
activity (compared with the promoter-
only construct) between the two different
alleles of rs1466535. In both the forward
and reverse directions, the T (nonrisk) allele
significantly reduced luciferase activity.
This finding is consistent with the disrup-
tion of SREP-1 binding observed in the
EMS assay as well as the LRP1 gene-expres-
sion findings in arterial tissue.
Discussion
We report an association of a common and
potentially functional variant in LRP1 withrisk of AAA. The association with LRP1with AAA remained
after adjustment for cardiovascular risk factors and further-
more, no association of rs1466535 was seen in data from
association studies of coronary artery disease, blood pres-
sure, diabetes, or hyperlipidaemia, suggesting that this
association is AAA specific rather than associated with
cardiovascular disease in general. The risk allele is common
(MAF ¼ 0.62) such that roughly 38% of individuals of
white European origin will carry two risk alleles and have
an approximately 14% higher risk of developing AAA
Figure 3. Electrophoretic Mobility Shift Assay Demonstrating
Allele-Specific Transcription Factor Binding to rs1466535
Lane A: binding of nuclear extract to labeled oligonucleotide con-
taining rs1466535 Tallele; lane B: T-allele binding with addition of
excess unlabeled T-allele DNA competitor. The remaining band
indicates a nonspecific protein-DNA interaction. Lane C: binding
of nuclear extract to labeled oligonucleotide containing C allele.
Lane D: C-allele binding with addition of excess unlabeled C-allele
probe. Elimination of bands present in lane C indicates the
binding of a specific protein. Lane E: C-allele-labeled oligonucleo-
tide with addition of excess unlabeled fSREBP-1 (a transcription
factor known to play an important role in LRP1 transcription)
DNA competitor. The reduction in intensity of the lower band
indicates that this binding is likely to be due to SREBP-1. Lane F:
C-allele-labeled oligonucleotide with addition of excess non-
SREBP-1-binding oligonucleotide competitor (sequence available
on request) as a negative control. Lane G: binding of nuclear
extract to labeled SREBP-1 consensus sequence, the lower band
migrates with the putative SREBP-1 bound to the C allele. Lane H:
SREBP-1 consensus sequence with the addition of excess SREBP-1
unlabeled competitor DNA. The lower band is eliminated, indi-
cating this band represents the DNA-SREBP-1 complex. Together,
these results suggest that rs1466535[T] removes a binding site
for SREBP-1 in vitro.than noncarriers. Interestingly, in South Asian popula-
tions, who rarely develop AAA, the allele frequency of
the rs1466535 C (risk) allele is lower (0.54), whereas in
African American populations (who have a risk of AAA in
between that of South Asians and white Europeans) the
risk-allele frequency is higher (0.83).23
Although the association study by itself cannot impli-
cate LRP1 as the causal gene at the locus, other data
support its candidacy. Early studies on aneurysmal aortic
tissue identified MMP9 as having a prime role in the aneu-
rysmal degradation of the aortic wall.24–26 LRP1 has been
shown to have a role in the regulation ofMMP9 expression
in response to tPA binding to the LRP1 receptor,27 as well as
a direct effect on MMP9 cellular processing.28 In addition
to this, LRP1 knockout mice are prone to aneurysm forma-The Americantion.29 These murine models have demonstrated that LRP1
is essential for the maintenance of vascular wall integrity,
particularly in the presence of high plasma lipid levels,30
and that this effect is mediated via PDGF receptor beta
and Smad signaling.29 Paradoxically, we observed higher
LRP1 expression in aortic tissue in those carrying the risk
allele for rs1466535, data supported by the findings from
the luciferase assay; therefore, whether the risk of AAA
relates to higher or lower expression of LRP1 remains to
be established. The magnitude of the observed difference
in gene expression between genotype groups was small,
and therefore caution needs to be exercised in its interpre-
tation. It is possible that this degree of change in expres-
sion over a lifetime could have an impact on AAA risk;
alternately, interaction of the genotype with other AAA
risk factors could result in a much larger change in LRP1
expression in the aneurysmal wall in susceptible individ-
uals. There are no immunohistochemical or expression
studies reporting the identification, location, or cellular co-
localization of LRP1 in the normal abdominal aortic wall or
in aneurysmal aortic tissue, and further investigation of
the role of LRP1 in aneurysmal disease is necessary. Simi-
larly, although we found evidence that rs1466535 C allele
might create a binding site for SREBP-1, whether this is
responsible for the association of the locus with risk of
AAA requires further elucidation and more investigation
into the determination of the function of this and other
SNPs in the region is warranted.
LRP1 is a large endocytic transmembrane receptor
named because it contains three separate clusters of
ligand-binding domains that bear structural similarity to
that of the other LDL receptors. It is, however, far larger
than the other LDL receptors and has a more diverse range
of functions. This variant (rs1466535) has not been associ-
ated with circulating lipid levels in large cohort studies,31
but unrelated SNPs in this region have demonstrated asso-
ciation with triglyceride and HDL levels but without
evidence of an increased risk of CAD.15 The fact that
rs1466535 alters expression levels in aortic rather than in
hepatic tissue suggests that its effect might not be via circu-
lating lipid levels, although the mechanism whereby the
higher expression levels of LRP1 in rs1466535 C-allele
carriers leads to an increased risk of AAA is unclear.
Previous large-scale genetic association studies for AAA
have discovered variants in 9p21.3 and DAB2IP.7,8 These
loci are involved in modulating cellular senescence and
proliferation32–35 and inflammation.36 LRP1 knockout
mice develop aortic aneurysms secondary to a proliferative
smooth-muscle phenotype29 and mutations in ACTA2
[MIM 102620] and TGFBR2 [MIM 190182], causative for
thoracic aortic aneurysms, also alter vascular smooth-
muscle cells (VSMCs) in favor of excessive prolifera-
tion.37–39 Taken together, the data from GWAS so far point
to pathways involved in the differentiation of VSMCs as
important in the development of AAA.
Currently, there are no specific medical treatments avail-
able for AAA, and repair (endovascular or open surgery)Journal of Human Genetics 89, 619–627, November 11, 2011 625
when the aneurysms reaches a size of more than 5.5 cm,
becomes symptomatic, or presents acutely following
rupture is the only therapeutic option. Our findings
suggest a mechanism contributing to AAA formation via
the LRP1 pathway, and exploration of this mechanism
could provide future therapeutic approaches to preventing
the development and/or progression of AAA.
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